Saturday 17 October 2026
Export CMPX’s income statement to Excel — free account
Compass Therapeutics, Inc.
CMPX Healthcare Biotechnology
Compass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00. In the quarter to June 2026, EPS grew 7.14% and free cash flow fell 26.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow CMPX
| Mar '18 | Dec '18 | Mar '19 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
P/S ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
Altman Z-Score |
— | — | — | — | — | — | — | — | 3.98 | — |
P/FCF ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | — | 3.28 | — |
P/Operating CF |
— | — | — | — | — | — | — | — | (21.74) | — |
P/B ratio |
— | — | — | — | — | — | — | — | 1.59 | — |
Price to Tangible BV |
— | — | — | — | — | — | — | — | 1.59 | — |
EV/Sales |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/EBITDA |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/Operating CF |
— | — | — | — | — | — | — | — | (1.74) | — |
EV/FCF |
— | — | — | — | — | — | — | — | (1.74) | — |
Quick Ratio |
0.00 | 0.00 | 0.06 | 2.58 | 4.66 | 13.59 | 11.54 | 19.54 | 14.28 | 14.96 |
Current Ratio |
0.00 | 0.00 | 0.06 | 2.67 | 4.97 | 13.84 | 12.05 | 19.73 | 14.96 | 15.02 |
Net Debt/EBITDA |
0.00 | (4,409.06) | 0.15 | 0.33 | 1.49 | 1.80 | 4.60 | 2.95 | 2.24 | 2.86 |
Debt/Assets |
0.00% | 2,951,469.39% | 0.00% | 48.94% | 17.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (1.71) | 0.00 | (0.13) | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Operating CF/Net income |
1.00 | 935.53 | 0.91 | 0.91 | 0.91 | 0.24 | 0.87 | 0.96 | 0.91 | 0.74 |
Capex/Depreciation |
— | 0.00 | — | (0.22) | 0.02 | (0.89) | (0.03) | 0.02 | (0.43) | 0.12 |
Interest Coverage |
(350.00) | (0.05) | (9.94) | (27.73) | (316.05) | (2,823.52) | (17.65) | — | — | — |
| 100.72% | 0.08% | 0.08% | 58.55% | 75.01% | (91.30%) | (24.38%) | (25.74%) | (36.07%) | (41.29%) | |
| 0.00% | (1,469.39%) | (734.69%) | (228.69%) | (71.70%) | (79.92%) | (22.20%) | (23.84%) | (33.22%) | (36.94%) | |
ROIC |
0.00% | (0.03%) | 0.00% | 0.00% | (789.04%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
101.45% | 1.16% | 50.99% | (172.27%) | (71.55%) | (59.24%) | (21.77%) | (28.91%) | (39.74%) | (33.93%) |
Average Days of Receivables |
0.00 | — | — | — | — | — | — | — | 0.00 | — |
Research and Development Expense of Revenue |
— | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4,981.41% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,780.35% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,007.06% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | — | — | 0.59 | — |
Graham Number |
— | — | — | — | — | — | — | — | 0.00 | — |
Earnings Yield |
— | — | — | — | — | — | — | — | (25.52%) | — |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | (22.55%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Operating CF per Share |
(0.01) | (0.65) | (0.01) | (4.74) | (0.87) | (0.31) | (0.32) | (0.32) | (0.33) | (0.31) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.07) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.01) | (0.65) | (0.01) | (4.81) | (0.87) | (0.34) | (0.32) | (0.32) | (0.33) | (0.31) |
Cash per Share |
0.00 | 0.00 | 0.00 | 3.78 | 1.53 | 2.30 | 1.77 | 1.20 | 0.92 | 1.32 |
Shareholders Equity per Share |
(0.01) | (1.63) | (0.01) | (17.73) | 1.30 | 2.23 | 1.73 | 1.17 | 0.91 | 1.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.01) | (1.63) | (0.01) | (17.73) | 1.30 | 2.23 | 1.73 | 1.17 | 0.91 | 1.25 |
Free Cash Flow |
(0.03) | (33.68) | (0.03) | (32.21) | (26.76) | (21.12) | (34.16) | (40.65) | (44.90) | (49.17) |
Working Capital |
(0.03) | (8.46) | (0.07) | 16.42 | 40.10 | 136.47 | 178.62 | 146.08 | 123.88 | 195.85 |
Capital Expenditures |
— | (2.02) | — | (0.47) | 0.04 | (1.45) | (0.04) | (0.03) | (0.04) | (0.02) |
Net Current Asset Value |
(0.03) | (149.39) | (0.07) | (122.75) | 38.24 | 133.43 | 176.78 | 145.54 | 117.58 | 187.02 |
EV/EBIT |
— | — | — | — | — | — | — | — | 0.00 | — |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | — | — | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.36 | — | 0.57 | 2.14 | 0.72 | 0.70 | (1.49) | 0.29 | (1.97) |
Cash ROIC |
101.16% | (56.27%) | 49.92% | 41.06% | (27.78%) | (7.42%) | (9.28%) | (13.50%) | (17.82%) | (12.12%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | — | 0.00 | — |
Accounts Payable Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 1.18 | — | 1.18 | 0.85 | 0.96 | 2.12 | 3.74 | 3.17 | 1.92 |
Average Assets |
0.00 | 0.00 | 0.00 | 15.19 | 41.15 | 102.83 | 176.70 | 178.26 | 148.64 | 180.00 |
Average Common Equity |
(0.03) | (42.40) | (42.42) | (59.34) | (39.33) | 90.01 | 160.86 | 165.09 | 136.89 | 161.01 |
Columns are period end dates